Modern approaches to treatment of castration-resistant prostate cancer using targeted radionuclide therapy in patients with bone metastases
Year: 2024
Type: article
Abstract: Treatment of metastatic castration-resistant prostate cancer (mCRPC) is an important problem. At this disease stage, some of the most pronounced symptoms worsening the quality of life develop: bone metastases-associated pain and pathological fractures. As a rule, mCRPC causes death due to prostate cancer progression. One of the 2nd line pharmaceuticals to treat mCRPC is Radium-223 dichloride [223Ra]. The use of Radium-223 increases overall survival, decreases the size, and in some cases, the number of metastatic lesions in the bones, decreases the intensity of pain syndrome and consequently the need for analgesics including narcotics. Radium-223 has a favorable safety profile and is tolerated well by the majority of patients. The review presents real clinical data on the use of Radium-223 in various countries including Russia and a network meta-analysis on the safety of mCRPC therapy using Radium-223 in combination with new antiandrogens.
Source: Cancer Urology
Institution: Ministry of Health of the Russian Federation
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W4408094482